全文获取类型
收费全文 | 4169篇 |
免费 | 315篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 159篇 |
妇产科学 | 91篇 |
基础医学 | 614篇 |
口腔科学 | 87篇 |
临床医学 | 517篇 |
内科学 | 639篇 |
皮肤病学 | 33篇 |
神经病学 | 428篇 |
特种医学 | 120篇 |
外国民族医学 | 1篇 |
外科学 | 773篇 |
综合类 | 49篇 |
一般理论 | 1篇 |
预防医学 | 401篇 |
眼科学 | 105篇 |
药学 | 235篇 |
中国医学 | 23篇 |
肿瘤学 | 166篇 |
出版年
2023年 | 26篇 |
2022年 | 49篇 |
2021年 | 115篇 |
2020年 | 34篇 |
2019年 | 66篇 |
2018年 | 100篇 |
2017年 | 75篇 |
2016年 | 79篇 |
2015年 | 85篇 |
2014年 | 110篇 |
2013年 | 171篇 |
2012年 | 255篇 |
2011年 | 273篇 |
2010年 | 153篇 |
2009年 | 119篇 |
2008年 | 273篇 |
2007年 | 254篇 |
2006年 | 244篇 |
2005年 | 229篇 |
2004年 | 229篇 |
2003年 | 224篇 |
2002年 | 191篇 |
2001年 | 59篇 |
2000年 | 44篇 |
1999年 | 48篇 |
1998年 | 28篇 |
1997年 | 32篇 |
1996年 | 26篇 |
1995年 | 24篇 |
1994年 | 25篇 |
1993年 | 20篇 |
1992年 | 61篇 |
1991年 | 51篇 |
1990年 | 47篇 |
1989年 | 37篇 |
1988年 | 38篇 |
1987年 | 43篇 |
1986年 | 47篇 |
1985年 | 50篇 |
1984年 | 61篇 |
1983年 | 34篇 |
1982年 | 52篇 |
1981年 | 26篇 |
1980年 | 29篇 |
1979年 | 25篇 |
1978年 | 32篇 |
1977年 | 23篇 |
1976年 | 19篇 |
1975年 | 16篇 |
1974年 | 12篇 |
排序方式: 共有4494条查询结果,搜索用时 15 毫秒
51.
Lisa Shea Jacqueline Pesa Gabrielle Geonnotti Valerie Powell Caryl Kahn Wesley Peters 《Health expectations》2022,25(4):1979
IntroductionThe lack of racial/ethnic diversity in research potentially limits the generalizability of findings to a broader population, highlighting the need for greater diversity and inclusion in clinical research. Qualitative research (i.e., focus groups) was conducted to identify (i) the potential motivators and barriers to study participation across different races and ethnicities; (ii) preferred delivery of education and information to support healthcare decision‐making and the role of the community.MethodsPatient focus groups were conducted with 26 participants from the sponsor''s Patient Engagement Research Councils selected through subjective sampling. Recruitment prioritized adequate representation across different race/ethnic groups. Participation was voluntary and participants underwent a confidential interview process before selection. Narrative analysis was used to identify themes and draw insights from interactions. Experienced research specialists identified emerging concepts, and these were tested against new observations. The frequency of each concept was examined to understand its importance.ResultsBased on self‐selected race/ethnicity, participants were divided into five focus groups (Groups: African American/Black: 2; Hispanic/Latino, Asian American, and white: 1 each) and were asked to share their experiences/opinions regarding the stated objectives. Barriers to study participation included: limited awareness of opportunities to participate in research, fears about changes in standard therapy, breaking cultural norms/stigma, religion‐related concerns and mistrust of clinical research. Participants identified the importance of transparency by pharmaceutical companies and other entities to build trust and partnership and cited key roles that communities can play. The perceptions of the African American group regarding diversity/inclusion in research studies appeared to be different from other groups; a lack of trust in healthcare providers, concerns about historical instances of research abuse and the importance of prayer were cited.ConclusionThis study provided insights into barriers to study participation, and also highlighted the need for pharmaceutical companies and other entities to authentically engage in strategies that build trust within communities to enhance recruitment among diverse populations.Patient or Public ContributionThe data collected in the present study was provided by the participants in the focus groups. 相似文献
52.
53.
Amy C. Morrison Robert C. Reiner Jr. William H. Elson Helvio Astete Carolina Guevara Clara del Aguila Isabel Bazan Crystyan Siles Patricia Barrera Anna B. Kawiecki Christopher M. Barker Gissella M. Vasquez Karin Escobedo-Vargas Carmen Flores-Mendoza Alfredo A. Huaman Mariana Leguia Maria E. Silva Sarah A. Jenkins Wesley R. Campbell Eugenio J. Abente Robert D. Hontz Valerie A. Paz-Soldan John P. Grieco Neil F. Lobo Thomas W. Scott Nicole L. Achee 《Proceedings of the National Academy of Sciences of the United States of America》2022,119(26)
Over half the world’s population is at risk for viruses transmitted by Aedes mosquitoes, such as dengue and Zika. The primary vector, Aedes aegypti, thrives in urban environments. Despite decades of effort, cases and geographic range of Aedes-borne viruses (ABVs) continue to expand. Rigorously proven vector control interventions that measure protective efficacy against ABV diseases are limited to Wolbachia in a single trial in Indonesia and do not include any chemical intervention. Spatial repellents, a new option for efficient deployment, are designed to decrease human exposure to ABVs by releasing active ingredients into the air that disrupt mosquito–human contact. A parallel, cluster-randomized controlled trial was conducted in Iquitos, Peru, to quantify the impact of a transfluthrin-based spatial repellent on human ABV infection. From 2,907 households across 26 clusters (13 per arm), 1,578 participants were assessed for seroconversion (primary endpoint) by survival analysis. Incidence of acute disease was calculated among 16,683 participants (secondary endpoint). Adult mosquito collections were conducted to compare Ae. aegypti abundance, blood-fed rate, and parity status through mixed-effect difference-in-difference analyses. The spatial repellent significantly reduced ABV infection by 34.1% (one-sided 95% CI lower limit, 6.9%; one-sided P value = 0.0236, z = 1.98). Aedes aegypti abundance and blood-fed rates were significantly reduced by 28.6 (95% CI 24.1%, ∞); z = −9.11) and 12.4% (95% CI 4.2%, ∞); z = −2.43), respectively. Our trial provides conclusive statistical evidence from an appropriately powered, preplanned cluster-randomized controlled clinical trial of the impact of a chemical intervention, in this case a spatial repellent, to reduce the risk of ABV transmission compared to a placebo.Aedes-borne viral diseases (ABVDs) [e.g., dengue (DENV), chikungunya, Zika (ZIKV), and yellow fever] are devastating, expanding global public health threats that disproportionally affect low- and middle-income countries. DENV, one of the most rapidly increasing vector-borne infectious diseases, results in ∼400 million infections each year (1, 2), with 4 billion people at risk for infection annually (3). Currently, the primary means for ABVD prevention is controlling the primary mosquito vector, Aedes aegypti. Existing vector control interventions, however, have failed to prevent ABV transmission and epidemics (4–6).There is an urgent need to develop evidence-based guidance for the use of new and existing ABV vector control tools. The evidence base for vector control against ABVs is weak, despite considerable government investments in World Health Organization (WHO)-recommended control of larval habitats (larviciding, container removal) and ultra-low-volume insecticide spraying (4, 5, 7–9). These strategies continue to be implemented despite the lack of rigorously generated data from controlled clinical trials demonstrating they reduce ABV infection or disease (6). The only ABV intervention with a proven epidemiological impact in a cluster-randomized control trial (cRCT) assessed community mobilization to reduce mosquito larval habitats (10). A recent test-negative trial with Wolbachia-infected mosquitoes reported a significant reduction of DENV illness in Indonesia (11).Spatial repellents (SRs) are devices that contain volatile active ingredients that disperse in air. The active ingredients can repel mosquitoes from entering a treated space, inhibit attraction to human host cues, or disrupt mosquito biting and blood-feeding behavior and, thus, interfere with mosquito–human contact (12–14). Any of these outcomes reduce the probability of pathogen transmission. Pyrethroid-based SRs have shown efficacy in reducing malaria infections in China (15) and Indonesia (16). There have, however, been no clinical trials evaluating the protective efficacy (PE) of SRs against ABV infection or disease.To generate evidence for public health consideration, we conducted a double-blinded, parallel cRCT to demonstrate and quantify the PE of a transfluthrin-based SR to reduce ABV infection incidence over 2 y in a human cohort in Iquitos, Peru. 相似文献
54.
55.
56.
57.
58.
Emily A. Rauscher Stephanie L. Young Wesley T. Durham Joshua B. Barbour 《Health communication》2017,32(5):550-559
This study investigates how young women of egg-donating age perceive egg donation. Using institutional theory, this study demonstrates how participants frame a health care decision, such as egg donation, utilizing familial ideals. Results revealed that women expressed the importance of ownership over their genetic material and that familial ideals encourage an ideal way to create a family, which egg donation only fits as a last resort. Results show that familial ideals reach past the institution of family into broader decision making, such as that of health care. Further, results show that as more families are constructed through assisted reproductive technologies, attempts should be made to gradually alter the familial ideal to encompass novel medical technologies such as egg donation. 相似文献
59.
60.
Wesley H. Self MD MPH Joyce Mickanin MSN RN Carlos G. Grijalva MD MPH Freda H. Grant MT ASCP Michelle C. Henderson MSN RN Glenda Corley MT ASCP D. Glen Blaschke II MD Candace D. McNaughton MD MPH Tyler W. Barrett MD MSCI Thomas R. Talbot MD MPH Barbara R. Paul MD 《Academic emergency medicine》2014,21(3):274-282